TrialProceedings of the National Academy of Sciences of the United States of America2009

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.

Grazia Galli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.